Form 4: Cassava Sciences Director Acquires 10,000 Stock Options

Director Robert Eugene Anderson Jr. acquired 10,000 stock options in Cassava Sciences Inc. on May 9, 2024, according to a Form 4 filing.

Summary

• Robert Eugene Anderson Jr., a director of Cassava Sciences Inc., acquired 10,000 stock options on May 9, 2024.
• The options were granted at an exercise price of $21.11.
• The stock options vest over a one-year period at a rate of 1/12 per month.
• The options expire on May 9, 2034.
• The grant was made pursuant to the Non-employee Director Compensation Program approved by stockholders on May 4, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of stock options can be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to director compensation, which is a common practice in publicly traded companies. It provides transparency regarding the incentives provided to board members.

Comparison to Industry Standards

• Director compensation packages, including stock options, are a standard practice in the biotechnology industry to align the interests of board members with those of shareholders.
• The vesting schedule of 1/12 per month over one year is a typical vesting arrangement for stock options granted to directors.
• Comparing the size of this option grant to those of directors at similar-sized biotech companies (e.g., Anavex Life Sciences, ACADIA Pharmaceuticals) would provide context on whether this grant is standard or exceptional.

Stakeholder Impact

• The grant of stock options to a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates